Reder, Anthony T., MD

Professor
Director of Infusion Therapy, Chicago-Greater Illinois Chapter of the NMSS -- Clinical Advisory Committee, Chairman

Address: 5841 S. Maryland Ave., MC 2030
Chicago, IL 60637-1470
Telephone: 773-702-6204
Secretary: Gretchen Hendrie
Patient Calls: 773-702-6222
Fax: 773-702-9076
Education & Training
  • M.D., 1978, University of Michigan Medical School
  • Residency, 1982, University of Minnesota
  • Fellowship (NeuroImmunology), 1984, University of Chicago
  • Board Certified in Neurology and Psychiatry
Clinical Interests
  • Multiple sclerosis
  • Neuro-immune diseases
Research Interests
  • Multiple sclerosis
    • Interferon signaling in MS
    • Immune regulation in MS
    • Neuro-endocrine regulation in MS
    • Clinical Trials of new agents in MS
  • Fellowship training in MS
  • Undergraduate education in laboratory investigation
Teaching
  • One month each of Ward and Consults supervision and teaching of Neurology residents
  • Lectures to residents in Neurosurgery, Anesthesia, ENT, Rheumatology, Ophthalmology, and Medicine
  • Lectures to graduate students in the Committees on Neurobiology and Immunology, one each per year
  • Awarded NIH K24 for mentoring MS Fellows
Selected Publications
  1. Reder AT, Antel JP, Oger J, McFarland TA, Rosenkoetter M, and Arnason BGW:  Low T8 antigen density on lymphocytes in active MS.  Ann Neurol 16:242-249, 1984.
  2. Reder AT, Antel JP, & Arnason BGW:  T regulator cell surface antigens in MS. AnnNYAS 436:247-253, 1985
  3. Gurney ME, Apatoff BR, Spear GT, Baumel MJ, Antel JP, Bania MB, and Reder AT:  Neuroleukin:  A lymphokine product of lectin-stimulated T cells.  Science 234:574-581, 1986.
  4. Reder AT, Lowy MT, Meltzer HY, & Antel JP:  DST abnormalities in MS. Neurology 37:849-53, 1987
  5. Skias D, Kim D, Reder AT, Antel JP, Lancki D, and Fitch F:  Susceptibility of astrocytes to Class I MHC antigen-specific cytotoxicity.  J Immunol 138: 3254-3258, 1987.
  6. Maimone D, Gregory S, Arnason BGW, & Reder AT:  Cytokine levels in the CSF and sera in MS.  J Neuroimmunol 32:67-74, 1991.
  7. Reder AT:  Regulation of production of ACTH-like proteins in human MNC.  Immunology 77:436-442, 1992.
  8. Karaszewski JW, Reder AT, Anlar B, and Arnason BGW:  Increased high affinity beta-adrenergic receptor densities and cyclic AMP responses of CD8 cells in MS.  J Neuroimmunol. 43:1-7, 1993.
  9. The IFNβ Multiple Sclerosis Study Group (Manuscript Committee:  WA Sibley, GC Ebers, HS Panitch, and AT Reder):  Interferon beta-1b is effective in RRMS.  I. Clinical results.  Neurology 43:655-661, 1993.
  10. Reder AT, Lascola CD, Flanders SA, Maimone D, Jensen MA, Skias DD, and Lancki DW:  Astrocyte cytolysis by MHC class II-specific mouse T cell clones.  Transplantation 56:393-399, 1993.
  11. Porrini AM and Reder AT:  IFN-γ, IFN-β, and PGE1 affect monokine secretion:  Relevance to monocyte activation in MS.  Cell Immunol 157:428-438, 1994.
  12. Reder AT et al. & Jensen M:  Prostaglandins ameliorate EAE.  J Neuroimmunol 54:117-127, 1994
  13. Reder AT, Thapar M, and Jensen MA:  A reduction in serum glucocorticoids provokes EAE:  Implications for treatment of inflammatory brain disease.  Neurology 44:2289-2294, 1994.
  14. Reder AT & Arnason B: Trigeminal neuralgia in MS relieved by PGE. Neurology 45:1097-1100, 1995
  15. Whitaker JN, Kachelhofer RD, Bradley EL, Burgard S, Layton BA, Reder AT, Morrison W, Zhao GJ, and Paty DW:  Urinary MBP-like material as a correlate of the progression of MS.  Ann Neurol 38:625-632, 1995.
  16.  Byskosh PV and Reder AT:  IFN-β effects on cytokine mRNA in PMNC in MS, Mult Scler 1:262-269, 1996.
  17. Pliskin NH, Hamer DP, Goldstein DS, Towle VL, Reder AT, Noronha A, & Arnason BGW:  Improved delayed visual reproduction test performance in MS patients receiving IFN β-1b.  Neurology 47:1463-1468, 1996.
  18. Genç K, Dona DL, & Reder AT:  Increased CD80+ cells in active MS; reversal by IFN β-1b therapy.  J Clin Invest 99:2664-2671, 1997.
  19. Reder AT, Genç K, Byskosh PV, and Porrini AM: Monocyte activation in MS. Mult Sclerosis  4:162-168, 1998
  20. Reder, AT and Antel JP:  Injecting rationale into IFN-β therapy.  Neurology 54:2034-2035, 2000.
  21. Lublin F, Reingold SC, & NMSS Task Force on Placebo Controlled Clinical Trials in MS:  Placebo-controlled clinical trials in MS:  Ethical considerations in an era of available therapies.  Ann Neurol 49:677-681, 2001. 
  22. Feng X, Yau D, Holbrook C, and Reder AT:  Type I IFNs inhibit IL-10 production in activated human monocytes and stimulate IL-10 in T cells.  J IFN Cytokine Res 22:311-319, 2002.
  23. Feng X, Petraglia, AL, Chen M, Byskosh PV, Boos MD, and Reder AT:  Low expression of IFN-stimulated genes in active MS is linked to subnormal phosphorylation of STAT1.  J Neuroimmunol 129:105-115, 2002.
  24. Panitch H et al.:  IFN-b1-a Rx regimens in MS:  The EVIDENCE Trial. Neurology 59:1496-1506, 2002
  25. Miller DH et al.:  A controlled trial of Natalizumab for relapsing MS.  NEJM 348:15-23, 2003.
  26. Chang CH, Nyenhuis DL, Cella D, Luchetta T, Dineen K, & Reder AT:  Psychometric evaluation of the Chicago Multiscale Depression Inventory (CMDI) in MS patients.  Multiple Sclerosis, 9:160-170, 2003.
  27. Petkau AJ, White R, Ebers GC, Reder AT, Sibley WA, Lublin FD, Paty DW et al.:  Longitudinal analyses of the effects of neutralizing Abs on IFN b-1b in relapsing-remitting MS.  Multiple Sclerosis, 10:126-138, 2004.
  28. Feng X, Eide FF, Jiang H, & Reder AT:  AAV vector-mediated APOE expression in Alzheimer’s d. mice:  Low CNS immune response, long-term expression, & astrocyte specificity. Front Biosci 9:1540-1546 2004.
  29. Ahn J, Feng X, Patel N, Dhawan N, and Reder AT:  Abnormal levels of IFN-g receptors in active MS are normalized by IFN-b therapy:  Implications for control of apoptosis.  Front Biosci 9:1547-1555 2004.
  30. Dalton CM et al.  Effect of natalizumab on conversion of Gd enhancing lesions to T1 hypodense lesions in relapsing MS.  J Neurol 251:407-413, 2004.
  31. Reder AT & Oger JJ:  Anti-myelin oligodendrocyte glycoprotein Abs in MS.  Neurology 62:1922-1923, 2004
  32. Hamamcιoğlu K and Reder AT.  Current perspectives in pathogenesis and treatment of multiple sclerosis, Turkish Journal of Medical Sciences, 35:131-141, 2005.
  33. Polman CH, O’Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, Phillips T, Lublin FD, Giovannoni G, et al., Panzara MA, Sandrock AW, and AFFIRM Investigators.  A randomized placebo-controlled trial of natalizumab for relapsing multiple sclerosis, New Engl J Med 354:899-910, 2006.
  34. Banwell B, Reder A, Krupp L, Tenembaum S, Eraksoy M, Boiko A, Pohl D, Freedman M, Schelensky L, and Antonijevic I.  Safety and tolerability of interferon beta-1b in pediatric MS, Neurology, 66:472-476, 2006.
  35. Goodin DS, Frohman EM, Hurwitz B, O'Connor PW, Oger JJ, Reder AT, Stevens JC. Neutralizing antibodies to IFN-b:  Assessment of clinical & radiographic impact:  Evidence report, AAN, Neurology. 68:977-84, 2007.
  36. Hamamcιoğlu K and Reder AT.  Interferon-b regulates cytokines and BDNF:  Greater effect in relapsing than in progressive MS.  Multiple Sclerosis 13:459-470, 2007.
  37. Yamaguchi KD, Ruderman DL, Croze E, Wagner TC, Velichko S, Reder AT, and Salamon H.  IFN‑b‑regulated genes show abnormal expression in therapy‑naïve R-R MS MNC:  Gene expression analysis employing all reported protein-protein interactions.  J Neuroimmunology 195:116-120, 2008.
  38. Reder AT,  Velichko S, Yamaguchi KD,  Hamamcıoğlu K, Ku K,  Beekman J, Wagner TC, Perez HD, Salamon H, and Croze E.  IFN-b-1b induces transient and variable gene expression in R-R MS patients, independent of NAb or changes in IFN receptor RNA expression.  J IFN Cytokine Res 28:317-331, 2008.
  39. Birnbaum G, Cree B, Altafullah I, Zinser M, Reder AT.  Combining b-interferon and atorvastatin may increase disease activity in MS.  Neurology 71:1390-1395, 2008.
  40. Javed A, Balabanov R, Arnason BGW, Kelly TJ, Sweiss NJ, et al., and Reder AT:  Minor salivary gland inflammation in Devic’s disease and longitudinally extensive myelitis.  Multiple Sclerosis 14:809-814, 2008.
Back to Top